nodes	percent_of_prediction	percent_of_DWPC	metapath
Alprostadil—SLCO3A1—Conjugated Estrogens—osteoporosis	0.321	0.485	CbGbCtD
Alprostadil—SLCO2B1—Conjugated Estrogens—osteoporosis	0.129	0.195	CbGbCtD
Alprostadil—SLCO2B1—Estradiol—osteoporosis	0.113	0.171	CbGbCtD
Alprostadil—ABCC4—Conjugated Estrogens—osteoporosis	0.0986	0.149	CbGbCtD
Alprostadil—Dinoprostone—SLC51A—osteoporosis	0.00356	0.841	CrCbGaD
Alprostadil—Dinoprostone—CYP19A1—osteoporosis	0.000671	0.158	CrCbGaD
Alprostadil—Rhinitis—Conjugated Estrogens—osteoporosis	0.000276	0.0012	CcSEcCtD
Alprostadil—Skin disorder—Ibandronate—osteoporosis	0.000275	0.0012	CcSEcCtD
Alprostadil—Muscle spasms—Risedronate—osteoporosis	0.000275	0.0012	CcSEcCtD
Alprostadil—Influenza—Estradiol—osteoporosis	0.000275	0.00119	CcSEcCtD
Alprostadil—Hyperhidrosis—Ibandronate—osteoporosis	0.000274	0.00119	CcSEcCtD
Alprostadil—Hypoaesthesia—Conjugated Estrogens—osteoporosis	0.000274	0.00119	CcSEcCtD
Alprostadil—Nausea—Ergocalciferol—osteoporosis	0.000273	0.00119	CcSEcCtD
Alprostadil—Pharyngitis—Conjugated Estrogens—osteoporosis	0.000273	0.00119	CcSEcCtD
Alprostadil—Erythema—Pamidronate—osteoporosis	0.000272	0.00118	CcSEcCtD
Alprostadil—Abdominal pain—Etidronic acid—osteoporosis	0.00027	0.00117	CcSEcCtD
Alprostadil—Skin disorder—Calcitriol—osteoporosis	0.00027	0.00117	CcSEcCtD
Alprostadil—Sweating increased—Estradiol—osteoporosis	0.000268	0.00116	CcSEcCtD
Alprostadil—Flushing—Zoledronate—osteoporosis	0.000265	0.00115	CcSEcCtD
Alprostadil—Visual impairment—Conjugated Estrogens—osteoporosis	0.000265	0.00115	CcSEcCtD
Alprostadil—Anaemia—Risedronate—osteoporosis	0.000265	0.00115	CcSEcCtD
Alprostadil—Bronchitis—Estradiol—osteoporosis	0.000264	0.00115	CcSEcCtD
Alprostadil—Nervousness—Pamidronate—osteoporosis	0.000264	0.00115	CcSEcCtD
Alprostadil—Back pain—Pamidronate—osteoporosis	0.000263	0.00114	CcSEcCtD
Alprostadil—Muscle spasms—Pamidronate—osteoporosis	0.000262	0.00114	CcSEcCtD
Alprostadil—Dyspepsia—Estropipate—osteoporosis	0.00026	0.00113	CcSEcCtD
Alprostadil—Syncope—Risedronate—osteoporosis	0.000257	0.00112	CcSEcCtD
Alprostadil—Dyspepsia—Alendronate—osteoporosis	0.000256	0.00111	CcSEcCtD
Alprostadil—Cough—Ethinyl Estradiol—osteoporosis	0.000256	0.00111	CcSEcCtD
Alprostadil—Upper respiratory tract infection—Estradiol—osteoporosis	0.000255	0.00111	CcSEcCtD
Alprostadil—Pollakiuria—Estradiol—osteoporosis	0.000254	0.0011	CcSEcCtD
Alprostadil—Pain—Estropipate—osteoporosis	0.000253	0.0011	CcSEcCtD
Alprostadil—Dyspepsia—Raloxifene—osteoporosis	0.000252	0.0011	CcSEcCtD
Alprostadil—Loss of consciousness—Risedronate—osteoporosis	0.000252	0.00109	CcSEcCtD
Alprostadil—Anaemia—Pamidronate—osteoporosis	0.000251	0.00109	CcSEcCtD
Alprostadil—Cough—Risedronate—osteoporosis	0.00025	0.00109	CcSEcCtD
Alprostadil—Dyspepsia—Ibandronate—osteoporosis	0.00025	0.00108	CcSEcCtD
Alprostadil—Pain—Alendronate—osteoporosis	0.000249	0.00108	CcSEcCtD
Alprostadil—Erythema—Zoledronate—osteoporosis	0.000249	0.00108	CcSEcCtD
Alprostadil—Hyperglycaemia—Estradiol—osteoporosis	0.000248	0.00108	CcSEcCtD
Alprostadil—Hypertension—Risedronate—osteoporosis	0.000247	0.00107	CcSEcCtD
Alprostadil—Discomfort—Ethinyl Estradiol—osteoporosis	0.000247	0.00107	CcSEcCtD
Alprostadil—Pain—Raloxifene—osteoporosis	0.000245	0.00106	CcSEcCtD
Alprostadil—Syncope—Pamidronate—osteoporosis	0.000244	0.00106	CcSEcCtD
Alprostadil—Pain—Ibandronate—osteoporosis	0.000242	0.00105	CcSEcCtD
Alprostadil—Pruritus—Etidronic acid—osteoporosis	0.000242	0.00105	CcSEcCtD
Alprostadil—Acute coronary syndrome—Estradiol—osteoporosis	0.000242	0.00105	CcSEcCtD
Alprostadil—Back pain—Zoledronate—osteoporosis	0.00024	0.00105	CcSEcCtD
Alprostadil—Myocardial infarction—Estradiol—osteoporosis	0.00024	0.00104	CcSEcCtD
Alprostadil—Feeling abnormal—Alendronate—osteoporosis	0.00024	0.00104	CcSEcCtD
Alprostadil—Oedema—Ethinyl Estradiol—osteoporosis	0.00024	0.00104	CcSEcCtD
Alprostadil—Erythema—Conjugated Estrogens—osteoporosis	0.000239	0.00104	CcSEcCtD
Alprostadil—Loss of consciousness—Pamidronate—osteoporosis	0.000239	0.00104	CcSEcCtD
Alprostadil—Muscle spasms—Zoledronate—osteoporosis	0.000239	0.00104	CcSEcCtD
Alprostadil—Dry mouth—Risedronate—osteoporosis	0.000238	0.00104	CcSEcCtD
Alprostadil—Urinary tract infection—Estradiol—osteoporosis	0.000238	0.00104	CcSEcCtD
Alprostadil—Infection—Ethinyl Estradiol—osteoporosis	0.000238	0.00103	CcSEcCtD
Alprostadil—Cough—Pamidronate—osteoporosis	0.000237	0.00103	CcSEcCtD
Alprostadil—Pain—Calcitriol—osteoporosis	0.000237	0.00103	CcSEcCtD
Alprostadil—Convulsion—Pamidronate—osteoporosis	0.000236	0.00102	CcSEcCtD
Alprostadil—Hypertension—Pamidronate—osteoporosis	0.000235	0.00102	CcSEcCtD
Alprostadil—Diarrhoea—Etidronic acid—osteoporosis	0.000234	0.00102	CcSEcCtD
Alprostadil—Haematuria—Estradiol—osteoporosis	0.000234	0.00102	CcSEcCtD
Alprostadil—Body temperature increased—Estropipate—osteoporosis	0.000234	0.00102	CcSEcCtD
Alprostadil—Abdominal pain—Estropipate—osteoporosis	0.000234	0.00102	CcSEcCtD
Alprostadil—Feeling abnormal—Ibandronate—osteoporosis	0.000234	0.00102	CcSEcCtD
Alprostadil—Skin disorder—Ethinyl Estradiol—osteoporosis	0.000233	0.00101	CcSEcCtD
Alprostadil—Nervousness—Conjugated Estrogens—osteoporosis	0.000232	0.00101	CcSEcCtD
Alprostadil—Infection—Risedronate—osteoporosis	0.000232	0.00101	CcSEcCtD
Alprostadil—Back pain—Conjugated Estrogens—osteoporosis	0.000231	0.00101	CcSEcCtD
Alprostadil—Abdominal pain—Alendronate—osteoporosis	0.00023	0.001	CcSEcCtD
Alprostadil—Body temperature increased—Alendronate—osteoporosis	0.00023	0.001	CcSEcCtD
Alprostadil—Muscle spasms—Conjugated Estrogens—osteoporosis	0.00023	0.001	CcSEcCtD
Alprostadil—Sinusitis—Estradiol—osteoporosis	0.00023	0.001	CcSEcCtD
Alprostadil—Shock—Risedronate—osteoporosis	0.00023	0.000999	CcSEcCtD
Alprostadil—Anaemia—Zoledronate—osteoporosis	0.00023	0.000999	CcSEcCtD
Alprostadil—Discomfort—Pamidronate—osteoporosis	0.000229	0.000995	CcSEcCtD
Alprostadil—Skin disorder—Risedronate—osteoporosis	0.000227	0.000986	CcSEcCtD
Alprostadil—Abdominal pain—Raloxifene—osteoporosis	0.000226	0.000984	CcSEcCtD
Alprostadil—Body temperature increased—Raloxifene—osteoporosis	0.000226	0.000984	CcSEcCtD
Alprostadil—Abdominal pain—Ibandronate—osteoporosis	0.000224	0.000974	CcSEcCtD
Alprostadil—Body temperature increased—Ibandronate—osteoporosis	0.000224	0.000974	CcSEcCtD
Alprostadil—Syncope—Zoledronate—osteoporosis	0.000223	0.000969	CcSEcCtD
Alprostadil—Oedema—Pamidronate—osteoporosis	0.000222	0.000965	CcSEcCtD
Alprostadil—Haemoglobin—Estradiol—osteoporosis	0.000221	0.000961	CcSEcCtD
Alprostadil—Infection—Pamidronate—osteoporosis	0.000221	0.000959	CcSEcCtD
Alprostadil—Rhinitis—Estradiol—osteoporosis	0.000221	0.000959	CcSEcCtD
Alprostadil—Haemorrhage—Estradiol—osteoporosis	0.00022	0.000956	CcSEcCtD
Alprostadil—Body temperature increased—Calcitriol—osteoporosis	0.000219	0.000953	CcSEcCtD
Alprostadil—Abdominal pain—Calcitriol—osteoporosis	0.000219	0.000953	CcSEcCtD
Alprostadil—Hypoaesthesia—Estradiol—osteoporosis	0.000219	0.000952	CcSEcCtD
Alprostadil—Shock—Pamidronate—osteoporosis	0.000218	0.00095	CcSEcCtD
Alprostadil—Loss of consciousness—Zoledronate—osteoporosis	0.000218	0.00095	CcSEcCtD
Alprostadil—Pharyngitis—Estradiol—osteoporosis	0.000218	0.000949	CcSEcCtD
Alprostadil—Thrombocytopenia—Pamidronate—osteoporosis	0.000217	0.000945	CcSEcCtD
Alprostadil—Cough—Zoledronate—osteoporosis	0.000217	0.000943	CcSEcCtD
Alprostadil—Tachycardia—Pamidronate—osteoporosis	0.000217	0.000942	CcSEcCtD
Alprostadil—Urethral disorder—Estradiol—osteoporosis	0.000216	0.000938	CcSEcCtD
Alprostadil—Rash—Etidronic acid—osteoporosis	0.000215	0.000936	CcSEcCtD
Alprostadil—Convulsion—Zoledronate—osteoporosis	0.000215	0.000936	CcSEcCtD
Alprostadil—Dermatitis—Etidronic acid—osteoporosis	0.000215	0.000936	CcSEcCtD
Alprostadil—Hyperhidrosis—Pamidronate—osteoporosis	0.000215	0.000933	CcSEcCtD
Alprostadil—Syncope—Conjugated Estrogens—osteoporosis	0.000215	0.000933	CcSEcCtD
Alprostadil—Hypertension—Zoledronate—osteoporosis	0.000215	0.000933	CcSEcCtD
Alprostadil—Headache—Etidronic acid—osteoporosis	0.000214	0.00093	CcSEcCtD
Alprostadil—Asthenia—Estropipate—osteoporosis	0.000212	0.000922	CcSEcCtD
Alprostadil—Visual impairment—Estradiol—osteoporosis	0.000212	0.000922	CcSEcCtD
Alprostadil—PTGIR—GPCR ligand binding—WNT1—osteoporosis	0.000212	0.00205	CbGpPWpGaD
Alprostadil—PTGER1—GPCR ligand binding—WNT1—osteoporosis	0.000212	0.00205	CbGpPWpGaD
Alprostadil—Loss of consciousness—Conjugated Estrogens—osteoporosis	0.00021	0.000914	CcSEcCtD
Alprostadil—Pruritus—Estropipate—osteoporosis	0.000209	0.000909	CcSEcCtD
Alprostadil—Discomfort—Zoledronate—osteoporosis	0.000209	0.000909	CcSEcCtD
Alprostadil—Asthenia—Alendronate—osteoporosis	0.000209	0.000908	CcSEcCtD
Alprostadil—Cough—Conjugated Estrogens—osteoporosis	0.000209	0.000908	CcSEcCtD
Alprostadil—Hypotension—Pamidronate—osteoporosis	0.000207	0.000902	CcSEcCtD
Alprostadil—Convulsion—Conjugated Estrogens—osteoporosis	0.000207	0.000901	CcSEcCtD
Alprostadil—Dry mouth—Zoledronate—osteoporosis	0.000207	0.0009	CcSEcCtD
Alprostadil—Pruritus—Alendronate—osteoporosis	0.000206	0.000895	CcSEcCtD
Alprostadil—Dyspepsia—Risedronate—osteoporosis	0.000206	0.000894	CcSEcCtD
Alprostadil—Flushing—Estradiol—osteoporosis	0.000204	0.000888	CcSEcCtD
Alprostadil—Asthenia—Ibandronate—osteoporosis	0.000203	0.000884	CcSEcCtD
Alprostadil—PTGIR—Hemostasis—RAP1A—osteoporosis	0.000203	0.00196	CbGpPWpGaD
Alprostadil—Nausea—Etidronic acid—osteoporosis	0.000203	0.000882	CcSEcCtD
Alprostadil—Oedema—Zoledronate—osteoporosis	0.000203	0.000882	CcSEcCtD
Alprostadil—Diarrhoea—Estropipate—osteoporosis	0.000202	0.000879	CcSEcCtD
Alprostadil—Infection—Zoledronate—osteoporosis	0.000202	0.000876	CcSEcCtD
Alprostadil—Pruritus—Ibandronate—osteoporosis	0.000201	0.000872	CcSEcCtD
Alprostadil—Pain—Risedronate—osteoporosis	0.0002	0.000868	CcSEcCtD
Alprostadil—Shock—Zoledronate—osteoporosis	0.0002	0.000867	CcSEcCtD
Alprostadil—Diarrhoea—Alendronate—osteoporosis	0.000199	0.000866	CcSEcCtD
Alprostadil—Asthenia—Calcitriol—osteoporosis	0.000199	0.000865	CcSEcCtD
Alprostadil—Thrombocytopenia—Zoledronate—osteoporosis	0.000199	0.000863	CcSEcCtD
Alprostadil—Tachycardia—Zoledronate—osteoporosis	0.000198	0.000861	CcSEcCtD
Alprostadil—ABCC4—Platelet degranulation—IGF1—osteoporosis	0.000198	0.00191	CbGpPWpGaD
Alprostadil—PTGIR—GPCR downstream signaling—MGLL—osteoporosis	0.000198	0.00191	CbGpPWpGaD
Alprostadil—PTGER1—GPCR downstream signaling—MGLL—osteoporosis	0.000198	0.00191	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—CALCR—osteoporosis	0.000198	0.00191	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—PTH1R—osteoporosis	0.000198	0.00191	CbGpPWpGaD
Alprostadil—Feeling abnormal—Ethinyl Estradiol—osteoporosis	0.000197	0.000858	CcSEcCtD
Alprostadil—Skin disorder—Zoledronate—osteoporosis	0.000197	0.000856	CcSEcCtD
Alprostadil—Pruritus—Calcitriol—osteoporosis	0.000196	0.000853	CcSEcCtD
Alprostadil—Hyperhidrosis—Zoledronate—osteoporosis	0.000196	0.000852	CcSEcCtD
Alprostadil—Diarrhoea—Raloxifene—osteoporosis	0.000196	0.000852	CcSEcCtD
Alprostadil—Dyspepsia—Pamidronate—osteoporosis	0.000195	0.00085	CcSEcCtD
Alprostadil—Dizziness—Estropipate—osteoporosis	0.000195	0.00085	CcSEcCtD
Alprostadil—Oedema—Conjugated Estrogens—osteoporosis	0.000195	0.000849	CcSEcCtD
Alprostadil—Infection—Conjugated Estrogens—osteoporosis	0.000194	0.000843	CcSEcCtD
Alprostadil—Diarrhoea—Ibandronate—osteoporosis	0.000194	0.000843	CcSEcCtD
Alprostadil—ABCC4—Platelet activation, signaling and aggregation—FGB—osteoporosis	0.000194	0.00187	CbGpPWpGaD
Alprostadil—PTGER2—GPCR downstream signaling—PTH—osteoporosis	0.000193	0.00187	CbGpPWpGaD
Alprostadil—Dizziness—Alendronate—osteoporosis	0.000193	0.000837	CcSEcCtD
Alprostadil—Shock—Conjugated Estrogens—osteoporosis	0.000192	0.000835	CcSEcCtD
Alprostadil—PTGIR—GPCR ligand binding—PTHLH—osteoporosis	0.000192	0.00185	CbGpPWpGaD
Alprostadil—PTGER1—GPCR ligand binding—PTHLH—osteoporosis	0.000192	0.00185	CbGpPWpGaD
Alprostadil—Erythema—Estradiol—osteoporosis	0.000192	0.000833	CcSEcCtD
Alprostadil—Tachycardia—Conjugated Estrogens—osteoporosis	0.000191	0.000829	CcSEcCtD
Alprostadil—Pain—Pamidronate—osteoporosis	0.00019	0.000825	CcSEcCtD
Alprostadil—Diarrhoea—Calcitriol—osteoporosis	0.00019	0.000825	CcSEcCtD
Alprostadil—Skin disorder—Conjugated Estrogens—osteoporosis	0.00019	0.000825	CcSEcCtD
Alprostadil—Hypotension—Zoledronate—osteoporosis	0.00019	0.000824	CcSEcCtD
Alprostadil—Body temperature increased—Ethinyl Estradiol—osteoporosis	0.000189	0.000823	CcSEcCtD
Alprostadil—Abdominal pain—Ethinyl Estradiol—osteoporosis	0.000189	0.000823	CcSEcCtD
Alprostadil—Dizziness—Raloxifene—osteoporosis	0.000189	0.000823	CcSEcCtD
Alprostadil—Hyperhidrosis—Conjugated Estrogens—osteoporosis	0.000189	0.000821	CcSEcCtD
Alprostadil—ABCC4—Response to elevated platelet cytosolic Ca2+—IGF1—osteoporosis	0.000189	0.00182	CbGpPWpGaD
Alprostadil—PTGER2—GPCR downstream signaling—CNR2—osteoporosis	0.000189	0.00182	CbGpPWpGaD
Alprostadil—Dizziness—Ibandronate—osteoporosis	0.000187	0.000815	CcSEcCtD
Alprostadil—Rash—Estropipate—osteoporosis	0.000186	0.00081	CcSEcCtD
Alprostadil—ABCC4—Hemostasis—MGLL—osteoporosis	0.000186	0.0018	CbGpPWpGaD
Alprostadil—Dermatitis—Estropipate—osteoporosis	0.000186	0.000809	CcSEcCtD
Alprostadil—Nervousness—Estradiol—osteoporosis	0.000186	0.000809	CcSEcCtD
Alprostadil—Back pain—Estradiol—osteoporosis	0.000185	0.000805	CcSEcCtD
Alprostadil—Headache—Estropipate—osteoporosis	0.000185	0.000805	CcSEcCtD
Alprostadil—Body temperature increased—Risedronate—osteoporosis	0.000185	0.000803	CcSEcCtD
Alprostadil—Abdominal pain—Risedronate—osteoporosis	0.000185	0.000803	CcSEcCtD
Alprostadil—PTGIR—Hemostasis—FGA—osteoporosis	0.000184	0.00178	CbGpPWpGaD
Alprostadil—Muscle spasms—Estradiol—osteoporosis	0.000184	0.0008	CcSEcCtD
Alprostadil—Rash—Alendronate—osteoporosis	0.000184	0.000798	CcSEcCtD
Alprostadil—Dermatitis—Alendronate—osteoporosis	0.000183	0.000797	CcSEcCtD
Alprostadil—Feeling abnormal—Pamidronate—osteoporosis	0.000183	0.000795	CcSEcCtD
Alprostadil—Hypotension—Conjugated Estrogens—osteoporosis	0.000182	0.000793	CcSEcCtD
Alprostadil—Headache—Alendronate—osteoporosis	0.000182	0.000793	CcSEcCtD
Alprostadil—ABCC5—Disease—SOST—osteoporosis	0.000181	0.00175	CbGpPWpGaD
Alprostadil—ABCC5—Disease—PKM—osteoporosis	0.000181	0.00175	CbGpPWpGaD
Alprostadil—Rash—Raloxifene—osteoporosis	0.000181	0.000785	CcSEcCtD
Alprostadil—Dermatitis—Raloxifene—osteoporosis	0.00018	0.000784	CcSEcCtD
Alprostadil—PTGER1—Signaling by GPCR—MGLL—osteoporosis	0.000179	0.00173	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—MGLL—osteoporosis	0.000179	0.00173	CbGpPWpGaD
Alprostadil—Headache—Raloxifene—osteoporosis	0.000179	0.00078	CcSEcCtD
Alprostadil—Rash—Ibandronate—osteoporosis	0.000179	0.000777	CcSEcCtD
Alprostadil—Dermatitis—Ibandronate—osteoporosis	0.000179	0.000776	CcSEcCtD
Alprostadil—Dyspepsia—Zoledronate—osteoporosis	0.000179	0.000776	CcSEcCtD
Alprostadil—Headache—Ibandronate—osteoporosis	0.000178	0.000772	CcSEcCtD
Alprostadil—PTGER2—Signaling by GPCR—PTH—osteoporosis	0.000176	0.0017	CbGpPWpGaD
Alprostadil—Nausea—Estropipate—osteoporosis	0.000176	0.000763	CcSEcCtD
Alprostadil—Body temperature increased—Pamidronate—osteoporosis	0.000176	0.000763	CcSEcCtD
Alprostadil—Abdominal pain—Pamidronate—osteoporosis	0.000176	0.000763	CcSEcCtD
Alprostadil—Rash—Calcitriol—osteoporosis	0.000175	0.00076	CcSEcCtD
Alprostadil—Dermatitis—Calcitriol—osteoporosis	0.000175	0.00076	CcSEcCtD
Alprostadil—Headache—Calcitriol—osteoporosis	0.000174	0.000756	CcSEcCtD
Alprostadil—Pain—Zoledronate—osteoporosis	0.000173	0.000754	CcSEcCtD
Alprostadil—ABCC4—NRF2 pathway—AGER—osteoporosis	0.000173	0.00167	CbGpPWpGaD
Alprostadil—Nausea—Alendronate—osteoporosis	0.000173	0.000752	CcSEcCtD
Alprostadil—Dyspepsia—Conjugated Estrogens—osteoporosis	0.000172	0.000747	CcSEcCtD
Alprostadil—Asthenia—Ethinyl Estradiol—osteoporosis	0.000172	0.000747	CcSEcCtD
Alprostadil—Syncope—Estradiol—osteoporosis	0.000172	0.000747	CcSEcCtD
Alprostadil—ABCC5—Disease—PGLS—osteoporosis	0.000172	0.00166	CbGpPWpGaD
Alprostadil—ABCC5—Disease—ANTXR2—osteoporosis	0.000172	0.00166	CbGpPWpGaD
Alprostadil—PTGER2—Class A/1 (Rhodopsin-like receptors)—POMC—osteoporosis	0.000172	0.00166	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—CNR2—osteoporosis	0.000171	0.00165	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—PLEK—osteoporosis	0.00017	0.00165	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—ANXA2—osteoporosis	0.00017	0.00165	CbGpPWpGaD
Alprostadil—Nausea—Raloxifene—osteoporosis	0.00017	0.000739	CcSEcCtD
Alprostadil—Pruritus—Ethinyl Estradiol—osteoporosis	0.00017	0.000737	CcSEcCtD
Alprostadil—PTGIR—GPCR ligand binding—CALCA—osteoporosis	0.000169	0.00163	CbGpPWpGaD
Alprostadil—PTGER1—GPCR ligand binding—CALCA—osteoporosis	0.000169	0.00163	CbGpPWpGaD
Alprostadil—Nausea—Ibandronate—osteoporosis	0.000168	0.000732	CcSEcCtD
Alprostadil—Loss of consciousness—Estradiol—osteoporosis	0.000168	0.000732	CcSEcCtD
Alprostadil—PTGIR—Hemostasis—FGB—osteoporosis	0.000168	0.00162	CbGpPWpGaD
Alprostadil—Asthenia—Risedronate—osteoporosis	0.000168	0.000729	CcSEcCtD
Alprostadil—Feeling abnormal—Zoledronate—osteoporosis	0.000167	0.000727	CcSEcCtD
Alprostadil—Cough—Estradiol—osteoporosis	0.000167	0.000727	CcSEcCtD
Alprostadil—Pain—Conjugated Estrogens—osteoporosis	0.000167	0.000726	CcSEcCtD
Alprostadil—Hypertension—Estradiol—osteoporosis	0.000165	0.000719	CcSEcCtD
Alprostadil—Pruritus—Risedronate—osteoporosis	0.000165	0.000718	CcSEcCtD
Alprostadil—Nausea—Calcitriol—osteoporosis	0.000165	0.000716	CcSEcCtD
Alprostadil—Diarrhoea—Ethinyl Estradiol—osteoporosis	0.000164	0.000713	CcSEcCtD
Alprostadil—Discomfort—Estradiol—osteoporosis	0.000161	0.0007	CcSEcCtD
Alprostadil—PTGER2—Signaling by GPCR—WNT1—osteoporosis	0.000161	0.00155	CbGpPWpGaD
Alprostadil—Body temperature increased—Zoledronate—osteoporosis	0.00016	0.000697	CcSEcCtD
Alprostadil—Abdominal pain—Zoledronate—osteoporosis	0.00016	0.000697	CcSEcCtD
Alprostadil—PTGER2—GPCR downstream signaling—PTHLH—osteoporosis	0.00016	0.00155	CbGpPWpGaD
Alprostadil—Diarrhoea—Risedronate—osteoporosis	0.00016	0.000695	CcSEcCtD
Alprostadil—Dry mouth—Estradiol—osteoporosis	0.000159	0.000693	CcSEcCtD
Alprostadil—Asthenia—Pamidronate—osteoporosis	0.000159	0.000693	CcSEcCtD
Alprostadil—Dizziness—Ethinyl Estradiol—osteoporosis	0.000158	0.000689	CcSEcCtD
Alprostadil—Pruritus—Pamidronate—osteoporosis	0.000157	0.000683	CcSEcCtD
Alprostadil—PTGER2—Signaling Pathways—MGLL—osteoporosis	0.000157	0.00152	CbGpPWpGaD
Alprostadil—Oedema—Estradiol—osteoporosis	0.000156	0.000679	CcSEcCtD
Alprostadil—Infection—Estradiol—osteoporosis	0.000155	0.000675	CcSEcCtD
Alprostadil—Dizziness—Risedronate—osteoporosis	0.000154	0.000671	CcSEcCtD
Alprostadil—Abdominal pain—Conjugated Estrogens—osteoporosis	0.000154	0.000671	CcSEcCtD
Alprostadil—Body temperature increased—Conjugated Estrogens—osteoporosis	0.000154	0.000671	CcSEcCtD
Alprostadil—Shock—Estradiol—osteoporosis	0.000154	0.000669	CcSEcCtD
Alprostadil—PTGER2—Signaling Pathways—LRP5—osteoporosis	0.000153	0.00148	CbGpPWpGaD
Alprostadil—PTGER1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6R—osteoporosis	0.000153	0.00147	CbGpPWpGaD
Alprostadil—Tachycardia—Estradiol—osteoporosis	0.000153	0.000663	CcSEcCtD
Alprostadil—SLCO2A1—Transmembrane transport of small molecules—ADCY5—osteoporosis	0.000152	0.00147	CbGpPWpGaD
Alprostadil—Diarrhoea—Pamidronate—osteoporosis	0.000152	0.00066	CcSEcCtD
Alprostadil—Skin disorder—Estradiol—osteoporosis	0.000152	0.00066	CcSEcCtD
Alprostadil—ABCC5—Metabolism—PKM—osteoporosis	0.000152	0.00147	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—FDPS—osteoporosis	0.000152	0.00147	CbGpPWpGaD
Alprostadil—Hyperhidrosis—Estradiol—osteoporosis	0.000151	0.000657	CcSEcCtD
Alprostadil—Rash—Ethinyl Estradiol—osteoporosis	0.000151	0.000657	CcSEcCtD
Alprostadil—Dermatitis—Ethinyl Estradiol—osteoporosis	0.000151	0.000656	CcSEcCtD
Alprostadil—Headache—Ethinyl Estradiol—osteoporosis	0.00015	0.000652	CcSEcCtD
Alprostadil—ABCC4—Transmembrane transport of small molecules—ANXA2—osteoporosis	0.000148	0.00142	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—SOST—osteoporosis	0.000148	0.00142	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—SOST—osteoporosis	0.000148	0.00142	CbGpPWpGaD
Alprostadil—Rash—Risedronate—osteoporosis	0.000147	0.00064	CcSEcCtD
Alprostadil—Dermatitis—Risedronate—osteoporosis	0.000147	0.00064	CcSEcCtD
Alprostadil—ABCC4—Hemostasis—TLN1—osteoporosis	0.000147	0.00142	CbGpPWpGaD
Alprostadil—Dizziness—Pamidronate—osteoporosis	0.000147	0.000638	CcSEcCtD
Alprostadil—PTGER2—Signaling Pathways—LRP6—osteoporosis	0.000146	0.00141	CbGpPWpGaD
Alprostadil—Headache—Risedronate—osteoporosis	0.000146	0.000636	CcSEcCtD
Alprostadil—ABCC5—Disease—GSN—osteoporosis	0.000146	0.00141	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—PTHLH—osteoporosis	0.000146	0.00141	CbGpPWpGaD
Alprostadil—Asthenia—Zoledronate—osteoporosis	0.000146	0.000633	CcSEcCtD
Alprostadil—ABCC4—Hemostasis—VCL—osteoporosis	0.000145	0.0014	CbGpPWpGaD
Alprostadil—SLCO3A1—Transmembrane transport of small molecules—ADCY5—osteoporosis	0.000144	0.00139	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—PGLS—osteoporosis	0.000144	0.00139	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—GPD2—osteoporosis	0.000144	0.00139	CbGpPWpGaD
Alprostadil—Pruritus—Zoledronate—osteoporosis	0.000144	0.000624	CcSEcCtD
Alprostadil—Nausea—Ethinyl Estradiol—osteoporosis	0.000142	0.000619	CcSEcCtD
Alprostadil—PTGER2—GPCR downstream signaling—CALCA—osteoporosis	0.000141	0.00136	CbGpPWpGaD
Alprostadil—Asthenia—Conjugated Estrogens—osteoporosis	0.00014	0.000609	CcSEcCtD
Alprostadil—Rash—Pamidronate—osteoporosis	0.00014	0.000609	CcSEcCtD
Alprostadil—Dermatitis—Pamidronate—osteoporosis	0.00014	0.000608	CcSEcCtD
Alprostadil—Headache—Pamidronate—osteoporosis	0.000139	0.000605	CcSEcCtD
Alprostadil—Diarrhoea—Zoledronate—osteoporosis	0.000139	0.000603	CcSEcCtD
Alprostadil—Nausea—Risedronate—osteoporosis	0.000139	0.000603	CcSEcCtD
Alprostadil—Pruritus—Conjugated Estrogens—osteoporosis	0.000138	0.000601	CcSEcCtD
Alprostadil—Dyspepsia—Estradiol—osteoporosis	0.000138	0.000598	CcSEcCtD
Alprostadil—Dizziness—Zoledronate—osteoporosis	0.000134	0.000583	CcSEcCtD
Alprostadil—Pain—Estradiol—osteoporosis	0.000134	0.000581	CcSEcCtD
Alprostadil—Diarrhoea—Conjugated Estrogens—osteoporosis	0.000134	0.000581	CcSEcCtD
Alprostadil—PTGER1—Signaling Pathways—PTH1R—osteoporosis	0.000133	0.00129	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—PTH1R—osteoporosis	0.000133	0.00129	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—CALCR—osteoporosis	0.000133	0.00129	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—CALCR—osteoporosis	0.000133	0.00129	CbGpPWpGaD
Alprostadil—Nausea—Pamidronate—osteoporosis	0.000132	0.000573	CcSEcCtD
Alprostadil—ABCC5—Metabolism—ATIC—osteoporosis	0.000132	0.00127	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—PNP—osteoporosis	0.000132	0.00127	CbGpPWpGaD
Alprostadil—PTGIR—GPCR downstream signaling—PTH—osteoporosis	0.000131	0.00126	CbGpPWpGaD
Alprostadil—PTGER1—GPCR downstream signaling—PTH—osteoporosis	0.000131	0.00126	CbGpPWpGaD
Alprostadil—PTGER2—GPCR ligand binding—POMC—osteoporosis	0.000131	0.00126	CbGpPWpGaD
Alprostadil—Dizziness—Conjugated Estrogens—osteoporosis	0.000129	0.000561	CcSEcCtD
Alprostadil—Feeling abnormal—Estradiol—osteoporosis	0.000129	0.00056	CcSEcCtD
Alprostadil—PTGER2—Signaling by GPCR—CALCA—osteoporosis	0.000128	0.00124	CbGpPWpGaD
Alprostadil—Rash—Zoledronate—osteoporosis	0.000128	0.000556	CcSEcCtD
Alprostadil—Dermatitis—Zoledronate—osteoporosis	0.000128	0.000555	CcSEcCtD
Alprostadil—PTGER1—GPCR downstream signaling—CNR2—osteoporosis	0.000127	0.00123	CbGpPWpGaD
Alprostadil—PTGIR—GPCR downstream signaling—CNR2—osteoporosis	0.000127	0.00123	CbGpPWpGaD
Alprostadil—Headache—Zoledronate—osteoporosis	0.000127	0.000552	CcSEcCtD
Alprostadil—ABCC5—Disease—LRP5—osteoporosis	0.000127	0.00123	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—TLN1—osteoporosis	0.000124	0.00119	CbGpPWpGaD
Alprostadil—Body temperature increased—Estradiol—osteoporosis	0.000124	0.000537	CcSEcCtD
Alprostadil—Abdominal pain—Estradiol—osteoporosis	0.000124	0.000537	CcSEcCtD
Alprostadil—Rash—Conjugated Estrogens—osteoporosis	0.000123	0.000535	CcSEcCtD
Alprostadil—Dermatitis—Conjugated Estrogens—osteoporosis	0.000123	0.000535	CcSEcCtD
Alprostadil—Headache—Conjugated Estrogens—osteoporosis	0.000122	0.000532	CcSEcCtD
Alprostadil—ABCC5—Disease—LRP6—osteoporosis	0.000122	0.00117	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—RAP1A—osteoporosis	0.000121	0.00117	CbGpPWpGaD
Alprostadil—Nausea—Zoledronate—osteoporosis	0.00012	0.000524	CcSEcCtD
Alprostadil—PTGER1—Signaling by GPCR—PTH—osteoporosis	0.000119	0.00115	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—PTH—osteoporosis	0.000119	0.00115	CbGpPWpGaD
Alprostadil—ABCC4—Platelet degranulation—TGFB1—osteoporosis	0.000119	0.00115	CbGpPWpGaD
Alprostadil—ABCC5—Disease—RPL24—osteoporosis	0.000117	0.00113	CbGpPWpGaD
Alprostadil—ABCC5—Disease—LTF—osteoporosis	0.000117	0.00113	CbGpPWpGaD
Alprostadil—Nausea—Conjugated Estrogens—osteoporosis	0.000116	0.000504	CcSEcCtD
Alprostadil—PTGIR—Class A/1 (Rhodopsin-like receptors)—POMC—osteoporosis	0.000116	0.00112	CbGpPWpGaD
Alprostadil—PTGER1—Class A/1 (Rhodopsin-like receptors)—POMC—osteoporosis	0.000116	0.00112	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—CNR2—osteoporosis	0.000116	0.00112	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—CNR2—osteoporosis	0.000116	0.00112	CbGpPWpGaD
Alprostadil—ABCC4—Response to elevated platelet cytosolic Ca2+—TGFB1—osteoporosis	0.000113	0.00109	CbGpPWpGaD
Alprostadil—Asthenia—Estradiol—osteoporosis	0.000112	0.000488	CcSEcCtD
Alprostadil—ABCC5—Metabolism—CA2—osteoporosis	0.000112	0.00108	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—OXCT1—osteoporosis	0.000112	0.00108	CbGpPWpGaD
Alprostadil—Pruritus—Estradiol—osteoporosis	0.000111	0.000481	CcSEcCtD
Alprostadil—ABCC4—Hemostasis—FGA—osteoporosis	0.00011	0.00106	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—MGLL—osteoporosis	0.000109	0.00105	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—WNT1—osteoporosis	0.000109	0.00105	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—WNT1—osteoporosis	0.000109	0.00105	CbGpPWpGaD
Alprostadil—PTGIR—GPCR downstream signaling—PTHLH—osteoporosis	0.000108	0.00105	CbGpPWpGaD
Alprostadil—PTGER1—GPCR downstream signaling—PTHLH—osteoporosis	0.000108	0.00105	CbGpPWpGaD
Alprostadil—Diarrhoea—Estradiol—osteoporosis	0.000107	0.000465	CcSEcCtD
Alprostadil—PTGER2—Signaling Pathways—P4HB—osteoporosis	0.000107	0.00103	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—MGLL—osteoporosis	0.000106	0.00102	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—MGLL—osteoporosis	0.000106	0.00102	CbGpPWpGaD
Alprostadil—ABCC5—NRF2 pathway—TGFB1—osteoporosis	0.000106	0.00102	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—PTH—osteoporosis	0.000104	0.001	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—LRP5—osteoporosis	0.000103	0.000999	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—LRP5—osteoporosis	0.000103	0.000999	CbGpPWpGaD
Alprostadil—Dizziness—Estradiol—osteoporosis	0.000103	0.000449	CcSEcCtD
Alprostadil—PTGER2—Signaling Pathways—RAP1A—osteoporosis	0.000102	0.000985	CbGpPWpGaD
Alprostadil—ABCC5—Disease—ACP5—osteoporosis	0.000101	0.000977	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—CNR2—osteoporosis	0.000101	0.000976	CbGpPWpGaD
Alprostadil—PTGER2—GPCR downstream signaling—ADCY5—osteoporosis	0.0001	0.000969	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—FGB—osteoporosis	9.99e-05	0.000965	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—NFATC1—osteoporosis	9.95e-05	0.000961	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—LRP6—osteoporosis	9.9e-05	0.000956	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—LRP6—osteoporosis	9.9e-05	0.000956	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—DKK1—osteoporosis	9.87e-05	0.000953	CbGpPWpGaD
Alprostadil—Rash—Estradiol—osteoporosis	9.86e-05	0.000428	CcSEcCtD
Alprostadil—Dermatitis—Estradiol—osteoporosis	9.85e-05	0.000428	CcSEcCtD
Alprostadil—PTGIR—Signaling by GPCR—PTHLH—osteoporosis	9.83e-05	0.000949	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—PTHLH—osteoporosis	9.83e-05	0.000949	CbGpPWpGaD
Alprostadil—Headache—Estradiol—osteoporosis	9.79e-05	0.000426	CcSEcCtD
Alprostadil—PTGIR—GPCR downstream signaling—CALCA—osteoporosis	9.53e-05	0.00092	CbGpPWpGaD
Alprostadil—PTGER1—GPCR downstream signaling—CALCA—osteoporosis	9.53e-05	0.00092	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—WNT1—osteoporosis	9.51e-05	0.000918	CbGpPWpGaD
Alprostadil—ABCC5—Disease—TPI1—osteoporosis	9.41e-05	0.000909	CbGpPWpGaD
Alprostadil—Nausea—Estradiol—osteoporosis	9.28e-05	0.000404	CcSEcCtD
Alprostadil—ABCC5—Metabolism—IDH2—osteoporosis	9.27e-05	0.000895	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—FGA—osteoporosis	9.25e-05	0.000893	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—ADCY5—osteoporosis	9.11e-05	0.00088	CbGpPWpGaD
Alprostadil—ABCC5—Disease—P4HB—osteoporosis	8.85e-05	0.000854	CbGpPWpGaD
Alprostadil—PTGER1—GPCR ligand binding—POMC—osteoporosis	8.82e-05	0.000852	CbGpPWpGaD
Alprostadil—PTGIR—GPCR ligand binding—POMC—osteoporosis	8.82e-05	0.000852	CbGpPWpGaD
Alprostadil—ABCC4—Platelet activation, signaling and aggregation—IGF1—osteoporosis	8.78e-05	0.000847	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—CYP27A1—osteoporosis	8.71e-05	0.000841	CbGpPWpGaD
Alprostadil—ABCC5—Disease—GAPDH—osteoporosis	8.68e-05	0.000839	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—CALCA—osteoporosis	8.66e-05	0.000836	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—CALCA—osteoporosis	8.66e-05	0.000836	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—PTHLH—osteoporosis	8.6e-05	0.00083	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—BMP2—osteoporosis	8.6e-05	0.00083	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—ACP5—osteoporosis	8.48e-05	0.000819	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—FGB—osteoporosis	8.41e-05	0.000812	CbGpPWpGaD
Alprostadil—SLCO2B1—Transmembrane transport of small molecules—ADCY5—osteoporosis	8.36e-05	0.000807	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—TLN1—osteoporosis	8.36e-05	0.000807	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—TLN1—osteoporosis	8.36e-05	0.000807	CbGpPWpGaD
Alprostadil—ABCC5—Disease—NFATC1—osteoporosis	8.25e-05	0.000797	CbGpPWpGaD
Alprostadil—ABCC5—Disease—DKK1—osteoporosis	8.19e-05	0.00079	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—PSMA2—osteoporosis	8.12e-05	0.000784	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—PSMA5—osteoporosis	8.12e-05	0.000784	CbGpPWpGaD
Alprostadil—ABCC5—Transmembrane transport of small molecules—ADCY5—osteoporosis	7.99e-05	0.000771	CbGpPWpGaD
Alprostadil—ABCC5—Disease—WNT1—osteoporosis	7.89e-05	0.000761	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—TPI1—osteoporosis	7.88e-05	0.000761	CbGpPWpGaD
Alprostadil—ABCC4—Ectoderm Differentiation—MYC—osteoporosis	7.69e-05	0.000742	CbGpPWpGaD
Alprostadil—ABCC5—Disease—FGA—osteoporosis	7.67e-05	0.000741	CbGpPWpGaD
Alprostadil—PTGIR—Hemostasis—IGF1—osteoporosis	7.59e-05	0.000733	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—CALCA—osteoporosis	7.57e-05	0.000731	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—P4HB—osteoporosis	7.41e-05	0.000715	CbGpPWpGaD
Alprostadil—PTGER2—GPCR downstream signaling—POMC—osteoporosis	7.38e-05	0.000713	CbGpPWpGaD
Alprostadil—ABCC4—NRF2 pathway—TGFB1—osteoporosis	7.33e-05	0.000708	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—GAPDH—osteoporosis	7.27e-05	0.000702	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—P4HB—osteoporosis	7.21e-05	0.000696	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—P4HB—osteoporosis	7.21e-05	0.000696	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—RAP1A—osteoporosis	7.08e-05	0.000684	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—PTH—osteoporosis	7.01e-05	0.000677	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—PTH—osteoporosis	7.01e-05	0.000677	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—RAP1A—osteoporosis	6.89e-05	0.000665	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—RAP1A—osteoporosis	6.89e-05	0.000665	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—KL—osteoporosis	6.87e-05	0.000664	CbGpPWpGaD
Alprostadil—ABCC5—Disease—ENO1—osteoporosis	6.84e-05	0.00066	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—CNR2—osteoporosis	6.83e-05	0.00066	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—CNR2—osteoporosis	6.83e-05	0.00066	CbGpPWpGaD
Alprostadil—PTGER1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—osteoporosis	6.8e-05	0.000657	CbGpPWpGaD
Alprostadil—PTGER1—GPCR downstream signaling—ADCY5—osteoporosis	6.78e-05	0.000655	CbGpPWpGaD
Alprostadil—PTGIR—GPCR downstream signaling—ADCY5—osteoporosis	6.78e-05	0.000655	CbGpPWpGaD
Alprostadil—ABCC5—Disease—PSMA2—osteoporosis	6.74e-05	0.000651	CbGpPWpGaD
Alprostadil—ABCC5—Disease—PSMA5—osteoporosis	6.74e-05	0.000651	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—NFATC1—osteoporosis	6.72e-05	0.000649	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—NFATC1—osteoporosis	6.72e-05	0.000649	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—POMC—osteoporosis	6.7e-05	0.000647	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—DKK1—osteoporosis	6.67e-05	0.000644	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—DKK1—osteoporosis	6.67e-05	0.000644	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—IL6R—osteoporosis	6.54e-05	0.000631	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—WNT1—osteoporosis	6.42e-05	0.00062	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—WNT1—osteoporosis	6.42e-05	0.00062	CbGpPWpGaD
Alprostadil—ABCC5—Disease—CALCA—osteoporosis	6.28e-05	0.000606	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—FGA—osteoporosis	6.25e-05	0.000603	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—FGA—osteoporosis	6.25e-05	0.000603	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—ADCY5—osteoporosis	6.16e-05	0.000594	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—ADCY5—osteoporosis	6.16e-05	0.000594	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—PTHLH—osteoporosis	5.81e-05	0.000561	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—PTHLH—osteoporosis	5.81e-05	0.000561	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—BMP2—osteoporosis	5.81e-05	0.000561	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—BMP2—osteoporosis	5.81e-05	0.000561	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—ENO1—osteoporosis	5.73e-05	0.000553	CbGpPWpGaD
Alprostadil—ABCC5—Disease—KL—osteoporosis	5.7e-05	0.000551	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—FGB—osteoporosis	5.68e-05	0.000549	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—FGB—osteoporosis	5.68e-05	0.000549	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—PSMA2—osteoporosis	5.64e-05	0.000545	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—PSMA5—osteoporosis	5.64e-05	0.000545	CbGpPWpGaD
Alprostadil—ABCC4—Transmembrane transport of small molecules—ADCY5—osteoporosis	5.54e-05	0.000534	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—PSMA2—osteoporosis	5.49e-05	0.00053	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—PSMA5—osteoporosis	5.49e-05	0.00053	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—PSMA2—osteoporosis	5.49e-05	0.00053	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—PSMA5—osteoporosis	5.49e-05	0.00053	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—ADCY5—osteoporosis	5.38e-05	0.00052	CbGpPWpGaD
Alprostadil—ABCC4—Platelet activation, signaling and aggregation—TGFB1—osteoporosis	5.26e-05	0.000508	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—SPP1—osteoporosis	5.21e-05	0.000503	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—CALCA—osteoporosis	5.11e-05	0.000494	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—CALCA—osteoporosis	5.11e-05	0.000494	CbGpPWpGaD
Alprostadil—PTGER1—GPCR downstream signaling—POMC—osteoporosis	4.99e-05	0.000482	CbGpPWpGaD
Alprostadil—PTGIR—GPCR downstream signaling—POMC—osteoporosis	4.99e-05	0.000482	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—IRS2—osteoporosis	4.71e-05	0.000455	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—KL—osteoporosis	4.64e-05	0.000448	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—KL—osteoporosis	4.64e-05	0.000448	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—LEP—osteoporosis	4.61e-05	0.000445	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—CYP19A1—osteoporosis	4.58e-05	0.000442	CbGpPWpGaD
Alprostadil—PTGIR—Hemostasis—TGFB1—osteoporosis	4.55e-05	0.000439	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—POMC—osteoporosis	4.53e-05	0.000437	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—POMC—osteoporosis	4.53e-05	0.000437	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—IGF1—osteoporosis	4.52e-05	0.000437	CbGpPWpGaD
Alprostadil—ABCC5—Disease—ADCY5—osteoporosis	4.47e-05	0.000431	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—IL6R—osteoporosis	4.42e-05	0.000427	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—IL6R—osteoporosis	4.42e-05	0.000427	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—ESR1—osteoporosis	4.4e-05	0.000425	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—IRS1—osteoporosis	4.11e-05	0.000397	CbGpPWpGaD
Alprostadil—ABCC5—Disease—MTHFR—osteoporosis	4.11e-05	0.000397	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—POMC—osteoporosis	3.96e-05	0.000382	CbGpPWpGaD
Alprostadil—ABCC5—Disease—IRS2—osteoporosis	3.91e-05	0.000377	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—IL6R—osteoporosis	3.86e-05	0.000373	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—IGF1—osteoporosis	3.81e-05	0.000368	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—ADCY5—osteoporosis	3.74e-05	0.000361	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—GPX1—osteoporosis	3.73e-05	0.00036	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—ADCY5—osteoporosis	3.64e-05	0.000351	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—ADCY5—osteoporosis	3.64e-05	0.000351	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—SPP1—osteoporosis	3.52e-05	0.00034	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—SPP1—osteoporosis	3.52e-05	0.00034	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—MTHFR—osteoporosis	3.44e-05	0.000332	CbGpPWpGaD
Alprostadil—ABCC5—Disease—IRS1—osteoporosis	3.41e-05	0.000329	CbGpPWpGaD
Alprostadil—ABCC5—Disease—IL6R—osteoporosis	3.2e-05	0.000309	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—IRS2—osteoporosis	3.18e-05	0.000307	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—IRS2—osteoporosis	3.18e-05	0.000307	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—LEP—osteoporosis	3.11e-05	0.000301	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—LEP—osteoporosis	3.11e-05	0.000301	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—ESR1—osteoporosis	2.97e-05	0.000287	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—ESR1—osteoporosis	2.97e-05	0.000287	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—IL6—osteoporosis	2.91e-05	0.000281	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—IRS1—osteoporosis	2.78e-05	0.000268	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—IRS1—osteoporosis	2.78e-05	0.000268	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—POMC—osteoporosis	2.75e-05	0.000266	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—TGFB1—osteoporosis	2.71e-05	0.000262	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—POMC—osteoporosis	2.68e-05	0.000258	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—POMC—osteoporosis	2.68e-05	0.000258	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—IL6R—osteoporosis	2.61e-05	0.000252	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—IL6R—osteoporosis	2.61e-05	0.000252	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—IGF1—osteoporosis	2.57e-05	0.000248	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—IGF1—osteoporosis	2.57e-05	0.000248	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—MYC—osteoporosis	2.29e-05	0.000221	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—TGFB1—osteoporosis	2.28e-05	0.000221	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—IL6—osteoporosis	1.97e-05	0.00019	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—IL6—osteoporosis	1.97e-05	0.00019	CbGpPWpGaD
Alprostadil—ABCC5—Disease—MYC—osteoporosis	1.9e-05	0.000183	CbGpPWpGaD
Alprostadil—ABCC5—Disease—TGFB1—osteoporosis	1.89e-05	0.000183	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—IL6—osteoporosis	1.72e-05	0.000166	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—MYC—osteoporosis	1.55e-05	0.000149	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—MYC—osteoporosis	1.55e-05	0.000149	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—TGFB1—osteoporosis	1.54e-05	0.000149	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—TGFB1—osteoporosis	1.54e-05	0.000149	CbGpPWpGaD
Alprostadil—ABCC5—Disease—IL6—osteoporosis	1.43e-05	0.000138	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—IL6—osteoporosis	1.16e-05	0.000112	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—IL6—osteoporosis	1.16e-05	0.000112	CbGpPWpGaD
